D&D Pharmatech has raised $137.1 million to advance treatments for neurodegenerative diseases and fibrosis. The series B will enable one D&D subsidiary to run phase 2 trials in Alzheimer's and Parkinson’s.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,